AU2022312986A1 - Annulated pyridazine compound - Google Patents
Annulated pyridazine compound Download PDFInfo
- Publication number
- AU2022312986A1 AU2022312986A1 AU2022312986A AU2022312986A AU2022312986A1 AU 2022312986 A1 AU2022312986 A1 AU 2022312986A1 AU 2022312986 A AU2022312986 A AU 2022312986A AU 2022312986 A AU2022312986 A AU 2022312986A AU 2022312986 A1 AU2022312986 A1 AU 2022312986A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- alkyl
- salt
- amino
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-120560 | 2021-07-21 | ||
| JP2021120560 | 2021-07-21 | ||
| PCT/JP2022/028138 WO2023003002A1 (ja) | 2021-07-21 | 2022-07-20 | 縮環ピリダジン化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022312986A1 true AU2022312986A1 (en) | 2024-03-07 |
Family
ID=84980224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022312986A Pending AU2022312986A1 (en) | 2021-07-21 | 2022-07-20 | Annulated pyridazine compound |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250084092A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4375274A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023003002A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240059614A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118234711A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022312986A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226995A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310264A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024000984A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202319055A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023003002A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| WO2022230912A1 (ja) | 2021-04-28 | 2022-11-03 | アステラス製薬株式会社 | 置換トリアジン化合物 |
| IL310992A (en) * | 2021-08-25 | 2024-04-01 | Ptc Therapeutics Inc | NLRP3 inhibitors |
| WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
| WO2023066377A1 (zh) | 2021-10-22 | 2023-04-27 | 索智生物科技(浙江)有限公司 | 一种含氮化合物、其制备方法及应用 |
| CN118234730A (zh) * | 2021-11-17 | 2024-06-21 | 豪夫迈·罗氏有限公司 | 杂环nlrp3抑制剂 |
| EP4499646A4 (en) * | 2022-03-31 | 2026-03-18 | Hangzhou Highlightll Pharmaceutical Co Ltd | NLRP3 Inflammasome Inhibitors |
| AR129012A1 (es) * | 2022-04-07 | 2024-07-03 | Takeda Pharmaceuticals Co | Derivados de piridazina fusionados |
| WO2024006559A1 (en) * | 2022-07-01 | 2024-01-04 | Neumora Therapeutics, Inc. | Modulators of nlrp3 inflammasome and related products and methods |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| WO2024109922A1 (zh) * | 2022-11-25 | 2024-05-30 | 成都赜灵生物医药科技有限公司 | 桥环并哒嗪类化合物及其用途 |
| KR20250135317A (ko) * | 2023-01-26 | 2025-09-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 신경퇴행성 질환의 치료에 유용한 1-아미노-4-페닐프탈라진 유도체 |
| EP4658644A1 (en) | 2023-01-31 | 2025-12-10 | Janssen Pharmaceutica NV | 2-(pyridazin-3-yl)-5-(trifluoromethyl)phenols as nlrp3 inhibitors |
| TW202448892A (zh) * | 2023-04-17 | 2024-12-16 | 大陸商上海拓界生物醫藥科技有限公司 | 稠合噠嗪類衍生物及其用途 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
| WO2026082103A1 (zh) * | 2024-10-16 | 2026-04-23 | 青岛博森泰科技有限公司 | 一种nlrp3抑制剂用于预防和/或治疗与体重增加相关的疾病或病症的用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1745039A4 (en) | 2004-05-08 | 2009-07-22 | Neurogen Corp | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES |
| WO2007130383A2 (en) * | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| GB201309508D0 (en) | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| GB201311953D0 (en) | 2013-07-03 | 2013-08-14 | Redx Pharma Ltd | Compounds |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| WO2018221433A1 (ja) * | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
| CN110914256A (zh) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| US12319701B2 (en) | 2019-10-04 | 2025-06-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP7356683B2 (ja) | 2020-01-31 | 2023-10-05 | 東京パワーテクノロジー株式会社 | ガスタービンの分解方法、組立方法、及び、治具 |
| CN115279739B (zh) | 2020-03-27 | 2025-07-22 | 尼科治疗有限公司 | 取代哒嗪化合物 |
| TW202231281A (zh) * | 2020-12-25 | 2022-08-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一類含噠嗪的化合物及其醫藥用途 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CN115433163A (zh) * | 2021-06-05 | 2022-12-06 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| JP2024529839A (ja) * | 2021-06-29 | 2024-08-14 | ズーマゲン バイオサイエンシーズ エルティーディー | Nlrp3モジュレーター |
| PL4363406T3 (pl) * | 2021-07-02 | 2026-01-05 | Astrazeneca Ab | Inhibitory inflamasomu nlrp3 |
| IL310992A (en) * | 2021-08-25 | 2024-04-01 | Ptc Therapeutics Inc | NLRP3 inhibitors |
| WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
| WO2023066377A1 (zh) * | 2021-10-22 | 2023-04-27 | 索智生物科技(浙江)有限公司 | 一种含氮化合物、其制备方法及应用 |
| AR129012A1 (es) * | 2022-04-07 | 2024-07-03 | Takeda Pharmaceuticals Co | Derivados de piridazina fusionados |
-
2022
- 2022-07-20 CA CA3226995A patent/CA3226995A1/en active Pending
- 2022-07-20 MX MX2024000984A patent/MX2024000984A/es unknown
- 2022-07-20 TW TW111127188A patent/TW202319055A/zh unknown
- 2022-07-20 CN CN202280061594.XA patent/CN118234711A/zh active Pending
- 2022-07-20 KR KR1020247005916A patent/KR20240059614A/ko active Pending
- 2022-07-20 JP JP2023536766A patent/JPWO2023003002A1/ja active Pending
- 2022-07-20 EP EP22845935.0A patent/EP4375274A4/en active Pending
- 2022-07-20 US US18/580,746 patent/US20250084092A1/en active Pending
- 2022-07-20 IL IL310264A patent/IL310264A/en unknown
- 2022-07-20 WO PCT/JP2022/028138 patent/WO2023003002A1/ja not_active Ceased
- 2022-07-20 AU AU2022312986A patent/AU2022312986A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024000984A (es) | 2024-06-19 |
| IL310264A (en) | 2024-03-01 |
| EP4375274A4 (en) | 2025-08-06 |
| WO2023003002A1 (ja) | 2023-01-26 |
| CA3226995A1 (en) | 2023-01-26 |
| JPWO2023003002A1 (cg-RX-API-DMAC7.html) | 2023-01-26 |
| US20250084092A1 (en) | 2025-03-13 |
| TW202319055A (zh) | 2023-05-16 |
| KR20240059614A (ko) | 2024-05-07 |
| CN118234711A (zh) | 2024-06-21 |
| EP4375274A1 (en) | 2024-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4375274A1 (en) | Annulated pyridazine compound | |
| KR102958021B1 (ko) | 피리다지닐 티아졸카르복시아미드 화합물 | |
| JP7675777B2 (ja) | 免疫調節剤としての複素環式化合物 | |
| AU2016355710B2 (en) | Modulators of ROR-gamma | |
| AU2022267160A1 (en) | Substituted triazine compound | |
| WO2024041606A1 (zh) | 具有抗kras突变肿瘤活性的化合物 | |
| WO2018228275A1 (zh) | 作为mnk抑制剂的杂环化合物 | |
| CN118772176A (zh) | 一种嘧啶并芳环化合物及其制备方法和用途 | |
| AU2017209935B2 (en) | New substituted cyanoindoline derivatives as NIK inhibitors | |
| CN108026045B (zh) | 用作RORγ调节剂的经过取代的四氢喹啉酮化合物 | |
| CN101903385B (zh) | 作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物 | |
| WO2014173291A1 (zh) | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 | |
| WO2013026025A1 (en) | Cyclohexyl azetidine derivatives as jak inhibitors | |
| CN105164114A (zh) | C-连接的杂环烷基取代的嘧啶类和它们的用途 | |
| CN118302417A (zh) | Nlrp3抑制剂 | |
| CA2828478A1 (en) | Serine/threonine kinase inhibitors | |
| EP4610258A1 (en) | Fused pyridazine derivative | |
| CN106565706B (zh) | 一种磺酰胺衍生物及其在药学中的应用 | |
| TW202409015A (zh) | 一種prmt5抑制劑、其製備方法及應用 | |
| TW200951136A (en) | Furo[3,2-d]pyrimidine derivatives | |
| CN122003418A (zh) | 作为malt1抑制剂的环戊并[e]吡唑并[1,5-a]嘧啶衍生物 | |
| EP3954680A1 (en) | Piperazine amide derivative, preparation method therefor, and use thereof in medicine | |
| TWI894448B (zh) | Ctla-4小分子降解劑及其應用 | |
| WO2023155900A1 (zh) | 一类五元并六元杂环化合物及其作为蛋白激酶抑制剂的用途 | |
| CN105636962B (zh) | 新型化合物、用途及其制备方法 |